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Abstract—Biological tumour volume (GTVPET) delineation on 18F-FDG PET acquired during 
induction chemotherapy (ICT) is challenging due to the reduced metabolic uptake and volume of the 
GTVPET. Automatic segmentation algorithms applied to 18F-FDG PET (PET-AS) imaging have been used 
for GTVPET delineation on 18F-FDG PET imaging acquired before ICT. However, their role has not been 
investigated in 18F-FDG PET imaging acquired after ICT. In this study we investigate PET-AS techniques, 
including ATLAAS a machine learned method, for accurate delineation of the GTVPET after ICT. Twenty 
patients were enrolled onto a prospective phase I study (FiGaRO). PET/CT imaging was acquired at 
baseline and 3 weeks following 1 cycle of induction chemotherapy. The GTVPET was manually delineated 
by a nuclear medicine physician and clinical oncologist. The resulting GTVPET was used as the reference 
contour. The ATLAAS original statistical model was expanded to include images of reduced metabolic 
activity and the ATLAAS algorithm was re-trained on the new reference dataset. Estimated GTVPET 
contours were derived using sixteen PET-AS methods and compared to the GTVPET using the Dice 
Similarity Coefficient (DSC). The mean DSC for ATLAAS, 60% Peak Thresholding (PT60), Adaptive 
Thresholding (AT) and Watershed Thresholding (WT) was 0.72, 0.61, 0.63 and 0.60 respectively. The 
GTVPET generated by ATLAAS compared favourably with manually delineated volumes and in 
comparison, to other PET-AS methods, was more accurate for GTVPET delineation after ICT. ATLAAS 
would be a feasible method to reduce inter-observer variability in multi-centre trials.  
 
Index Terms—Automated Segmentation, Head & Neck, Machine learning, PET/CT, Target delineation 
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I. INTRODUCTION 
Head and neck cancer (H&N) is the sixth most common tumour worldwide [1]. In the UK, H&N cancers account 
for 3% of all new cases and the rate of incidence has increased by 30% since the early 1990s [2]. Over the last 
10-20 years, Human Papillomavirus (HPV) has become an increasing cause of a subset of oropharyngeal 
squamous cell carcinomas (OPSCC) in the H&N [3]. Radiation therapy (RT) is often used to treat OPSCC and 
fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) aids target volume delineation 
(TVD) in RT planning. 18F-FDG PET discriminates the biological tumour volume (GTVPET) from healthy tissue 
with higher sensitivity and specificity compared to conventional anatomical imaging [4–11]. TVD is usually 
performed manually [6,7] and thus is prone to inter and intra-observer variability [12]. However, multidisciplinary 
approaches to TVD in H&N cancer have been shown to improve TVD accuracy. A multi-disciplinary TVD 
approach in H&N consists of a radiation oncologist (clinical oncologist, UK) , a neuro-radiologist, and if required, 
a head-and-neck surgeon [13]. However, it is time-consuming [14–16]. 
 
Inaccuracies during TVD can lead to higher organ at risk (OAR) doses and increased toxicity [17], and to tumour 
under-dose. This is critical for intensity-modulated radiotherapy (IMRT), which is characterised by steep dose 
gradients, further decreasing the margin for error [18]. Combined these errors could increase the rates of clinically 
significant geographical miss [18–20], local [19] and local regional recurrence [18]. 
 
A variety of PET automated segmentation (PET-AS) methods have been proposed to reduce variability in TVD 
[21]. Standardised uptake value max (SUVmax) thresholding is commonly used, especially in H&N, lung and 
cervical cancer [6]. SUVmax and SUVpeak are considered to be suitable for GTVPET auto-segmentation as they are 
less dependent upon accurate volume definition than other PET measures [22].  
 
More complex PET-AS such as adaptive iterative thresholding (AT) [23,24] have been shown to correlate with 
the GTVPET. Other methods have been shown to be promising including region growing (RG) [25], Watershed 
Transform (WT) [26,27] and clustering techniques, such as Fuzzy C-means (FCM) [28], Gaussian Mixture Model 
based Fuzzy C-means (GCM) as described by Hatt et al [29] and K-means (KM) [6]. However, current 
recommendations state that no validated quantitative approach for PET contouring will result in idealistic TVD 
in all cases [30] and that no single PET-AS method can be recommended for TVD [22]. 
 
Machine learned PET-AS methods show promise for accurate TVD. However, comparing machine learned PET-
AS is challenging due to the lack of a standardised validation imaging dataset [22]. A PET-AS methodology called 
Automatic decision Tree-based Learning Algorithm for Advanced Image Segmentation (ATLAAS) is an 
algorithm designed to select the most accurate PET-AS technique for a given PET image [31]. ATLAAS has been 
evaluated on pre-treatment 18F-FDG PET scans [32]. However, there is increasing use of multimodality therapy 
including surgery and chemotherapy [33] and this requires expanding the original statistical model and re-training 
the ATLAAS algorithm on a new reference dataset. 
 
Typically, RT planning is performed on CT imaging acquired before RT. Induction chemotherapy (ICT) before 
RT can lead to tumour downstaging and reduced GTVPET volume [34]. Therefore, tumour shape, size and volume 
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delineated on pre-ICT imaging may not be accurately represented when RT treatment starts. RT planning on 
PET/CT imaging acquired during ICT could improve the accuracy of RT planning. However, TVD during 
treatment with chemotherapy and/or radiotherapy is challenging due to the reduced metabolic activity and GTVPET 
volume. The aims of this study were to evaluate the feasibility of re-training a machine learned PET-AS method 
and assess the performance of PET-AS TVD on 18F-FDG PET imaging acquired after one cycle of ICT. 
 
II. MATERIALS AND METHODS 
A. Clinical Data 
An ongoing phase I, multi-centre, feasibility trial called FiGaRO (Chief Investigator: TGU) involving Guy’s 
and St Thomas’ Hospitals (London, UK) and Velindre Cancer Centre (Cardiff, UK) is investigating dose 
escalation to the residual 18F-FDG signal following 1 cycle of Cisplatin and 5-Fluorouracil (5FU) chemotherapy, 
in patients with primary OPSCC. The aim of the study is to improve tumour control rates whilst delivering 
acceptable toxicity levels. Ethical approval for the trial by the research ethics committee was granted in July 2012 
(REC: 12/LO/1724). Written informed consent was obtained from all patients. 
 
Twenty-three patients were enrolled between October 2013 and March 2017. One patient was excluded as ICT 
resulted in a GTVPET volume too small for effective dose escalation. Two other patients were excluded due to 
technical and unrelated medical problems. Twenty patients with OPSCC proceeded to have dose-escalated 
radiotherapy. Of the twenty scans, one scan had two separate GTVPET volumes, providing twenty-one GTVPET 
volumes for analysis. Patients had histologically confirmed OPSCC, assessed as either HPV negative by p16 
immunohistochemistry and in-situ hybridization for high-risk subtype DNA, or ‘intermediate’ or ‘high’ risk HPV 
positive, defined as having a greater than 10 pack/year smoking history and advanced N stage (TNM v7 N2b, 
N2c, N3) [3]. All patients were over 18 years old, staged with at least T2 tumours and planned for treatment with 
2 cycles of ICT followed by primary radical IMRT to the primary and bilateral neck nodes, with concurrent 
Cisplatin chemotherapy (chemo-IMRT). Exclusion criteria included previous radiotherapy to the H&N region, 
previous malignancy except for non-melanoma skin cancer, as well as previous or concurrent illness which could 
interfere with the completion of the radiotherapy plan or follow-up. The clinical pathway for recruited patients is 
shown in Supplementary data.  
 
B. 18F-FDG PET/CT imaging 
Patients underwent a planning 18F-FDG/CT scan in the treatment position using a H&N immobilisation shell, 
3 weeks following the first cycle of ICT. Planning 18F-FDG/CT scan consisted of a low dose CT for attenuation 
correction, then the 18F-FDG-PET, followed immediately by a contrast-enhanced CT. Scans were acquired with 
a 3 mm slice thickness. Patients were injected with 350+/- 10% MBq of 18F-FDG and rested for 90 minutes before 
PET/CT scanning (GE Discovery 710 and GE Discovery 690, General Electric Medical Systems, Waukesham 
WI). The PET scan was acquired with a field of view of 700 mm and a matrix of 256 x 256, resulting in a voxel 
dimension of 2.7 mm x 2.7 mm with a slice thickness of 3.2 mm. PET imaging was acquired using 4 minutes per 
bed position, with 3 beds in total. PET data were reconstructed with the ordered subset expectation maximisation 
(OSEM) reconstruction algorithm using time of flight information with 2 
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width at half maximum (FWHM) Gaussian post filter was applied to the data. Point spread function modelling 
techniques were not used. 
 
C. Manual GTVPET delineation after 1 cycle of chemotherapy 
Manual GTVPET delineation in this study was performed by a nuclear medicine physician and a radiation 
oncologist (clinical oncologist, UK). Delineation of the GTVPET was performed independently by each viewer 
using an TVD protocol. The initial GTVPET delineation was guided by a seed-based method and differences in 
delineation were resolved by an intermediary clinician. PET images for GTVPET TVD were displayed in SUV and 
visualised using an inverse linear colour scale with a fixed window level of SUV 0 – 10. Software used for GTVPET 
delineation at Guy’s & St Thomas’ PET Centre was Hermes Hybrid Viewer (Hermes Medical Solutions, Sweden) 
versions 2.2C and 2.6H and at Velindre Cancer Centre was Velocity AI version 2.7 (Varian Medical Systems, 
Palo Alto, USA) and ProSoma version 3.2 (OSL Oncology Systems Limited, UK). The GTVPET was used for RT 
planning and as the reference GTV in subsequent analyses. Whilst, consensus techniques can be used to reduce 
intra and inter-observer variability, GTVPET volumes obtained in the clinical environment cannot be considered a 
ground truth (GT), even with histopathological reference. GT volumes can only be obtained from phantom-based 
and simulated PET scans. Therefore, for these reasons and following the guidance of the Task Group 211 report 
comparisons of delineated GTVPET volumes were performed using Dice Similarity Coefficient (DSC) as DSC 
does not favour one delineation over the other [22]. Additionally, the Sensitivity and Positive Predictive Value 
(PPV) are also reported. DSC is calculated as twice the intersection of two defined GTVPET’s divided by the union 
of the two defined GTVPET volumes. A result of 1 means the delineated volumes are identical and a result of 0 
means a complete volume mismatch. Sensitivity is calculated as the number of true positives divided by the sum 
of the true positives and the false negatives. A result of 1 means the PET-AS identifies all voxels as tumour, 
whereas a result of 0 means the PET-AS identifies no voxels as tumour. PPV is calculated as the intersection of 
the reference GTVPET and the comparison GTVPET volume divided by the comparison GTVPET volumes. A result 
of 1 means the PET-AS method only identifies tumour voxels as tumour and a result of 0 means the PET-AS 
method does not identify tumour voxels. Tumour characteristics extracted from the manually defined GTVPET’s 
are presented in Supplementary Data (A). 
 
D. Development of ATLAASICT 
ATLAAS is a machine learned, decision tree-based, PET-AS methodology, optimised with a training dataset 
for which the segmentation outcome is known, for optimal performance in new clinical cases in which the outcome 
is not known. ATLAAS has been previously described in detail [31] and is incorporated into the Computational 
Environment for Radiotherapy Research (CERR) [35]. 
 
The ATLAAS statistical model was originally developed on pre-treatment H&N 18F-FDG PET imaging data and 
is built using the following image and tumour parameters: tumour to background ratio (TBR), metabolic tumour 
volume (MTV) and the Number of discrete Intensities (NI) within the tumour volume. NI is therefore a measure 
of tumour homogeneity. Hyper-parameters are parameters which are defined by the user, which can inform the 
training of a statistical model. Potential hyper-parameters for the ATLAAS statistical model include lymph node 
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size, the number of involved lymph nodes, the total number of distant metastases as well as patient characteristics 
including weight and age. However, hyper-parameters are not used in the development of the statistical model as 
the ATLAAS segmentation methodology is designed to be applied to PET images with limited user interaction 
and with no prior knowledge of the PET scan other than primary tumour location. The training database was built 
using the PETSTEP simulator [36]. PETSTEP uses a CT image and a map of the FDG uptake to generate a PET 
image from tumour contours that can be drawn by the user, regular in shape (e.g. spheroids) or automatically 
generated. The ATLAAS database was generated based upon existing PET/CT data of a fillable phantom with 
target tumour objects covering a range of differing characteristics working in the setting of diagnostic PET scans. 
The ATLAAS training database consists of a total of 100 regular spherical tumour objects with volumes and 
maximum uptake values in the range of 0.5 mL – 50 mL and 4000 Bq mL-1 – 40000 Bq mL-1 [31] (ATLAASORIG). 
The mean TBR [range] of the ATLAASORIG training dataset was 3.37 [1.55 – 4.78]. The ATLAASORIG training 
dataset was reconstructed using optimised subset expectation maximization reconstruction using 2 iterations and 
24 subsets with a point spread function of 4.9. 
 
Table I shows that ICT reduced the MTV, SUVmax, TBR and NI values when contoured using 42% of the SUVmax 
fixed thresholding and a one-tailed T-test showed a significant reduction (P < 0.05) in the extracted characteristics 
after ICT. A threshold of 42% of the SUVmax was chosen to standardise extraction of the tumour characteristics 
on the pre-ICT and post-ICT PET imaging, as manually defined GTVPET volumes were only delineated on post-
ICT PET imaging, which was used for RT planning. Following a previously published experiment [31,32], a new 
statistical model was developed by simulating an additional set of 100 synthetic target tumour objects with 
MTV’s, NI and TBR covering the range of values obtained from 10 FiGaRO clinical scans, with GTVPET contours 
used as a basis for target tumour simulation. The simulation process has been described previously [36]. Resulting 
synthetic PET scans had a matrix resolution of 256 x 256 with a voxel size of 2.7 mm x 2.7 mm and a slice 
thickness of 3.3 mm. Simulated PET scans were reconstructed using optimised subset expectation maximization 
reconstruction using 2 iterations and 24 subsets with a point spread function of 4.9. These reconstruction 
parameters were chosen to match the ATLAASORIG training dataset, whilst demonstrating ATLAAS’S robustness 
to PET imaging acquired from different centres. Simulated PET scans were combined with the ATLAASORIG 
training dataset to create the ATLAASICT dataset. FiGaRO clinical scans were used for tumour characteristic 
acquisition and as a basis for PET simulation only and were not incorporated into the ATLAASICT training dataset. 
These ranges were 1.59-21.25 mL, 28-63 and 0.57-3.5 for MTV, NI and TBR respectively. Figure 1 shows the 
range of MTV, TBR and NI for the FiGaRO trial PET data and ATLAASORIG (Figures 1a, 1c and 1e) and 
ATLAASICT datasets (Figures 1b, 1d and 1f). The post-ICT GTVPET have smaller MTV, lower TBR and lower NI 
than the ATLAASORIG dataset. The ATLAASICT dataset has MTV, TBR and NI values that overlap with the 
FiGaRO values and this was used to develop a new decision tree-based statistical model for ATLAAS. This model 
was used to delineate the GTVPET-AS for our study. 
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TABLE I 
MEAN [RANGE] MTV, TBR, SUVMAX AND NI ON 18F-FDG PET IMAGING ACQUIRED BEFORE AND AFTER ICT 
WHEN CONTOURED USING 42% SUVMAX FIXED THRESHOLDING. 
Parameter Before ICT 
18F-
FDG PET After ICT 
18F-FDG PET 
Mean MTV (mL)  9.67 [2.79 – 36.18] 7.43 [3.81 – 15.11] 
Mean TBR  2.16 [1.77 – 2.69] 1.79 [1.32-2.31] 
Mean SUVmax  16.05 [6.96 – 32.96] 10.93 [4.73 – 25] 
Mean NI  59.75 [45 – 65] 54.38 [63-42] 
 
E. Automatic GTVPET-AS delineation after 1 cycle of ICT 
GTVPET-AS was defined as the biological tissue delineated by the PET-AS methods well as the ATLAASICT 
statistical model. For threshold-based methods, a relative threshold ranging from 20-80%, in increments of 10%, 
of the SUVpeak (PT20-PT80) was used. AT is an adaptive iterative thresholding-based PET-AS method 
implemented in 3D, using background subtraction [23,24]. RG is a 3D Region-growing implementation with an 
automatic seed finder. In our implementation, RG stops when there is less than 5% change in the number of voxels 
included as tumour between one iteration and the next [25]. KM is a 3D K-means iterative clustering with custom 
stopping criterion [6]. KM2/KM3 use two and three clusters respectively. FCM is a 3D Fuzzy-C-means iterative 
clustering implementation with custom stopping criterion [28]. FCM2 uses two clusters. GCM is a 3D Gaussian 
Mixture Models based clustering with custom stopping criterion [37]. GCM3/GCM4 uses three and four clusters 
respectively. WT is a Watershed Transform-based implementation using a Sobel filter [26]. A total of 336 
GTVPET-AS volumes were delineated, 16 for each patient. 
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Figure 1: The range of MTV, TBR and NI for the FiGaRO trial PET data and ATLAASORIG (a, c and e) and 
ATLAASICT datasets (b, d and f) 
 
F. Statistical analysis  
All GTVPET-AS contours were compared to the GTVPET, using the DSC calculated using Matlab 2016b (The 
MathWorks Inc., Natick, Massachusetts, US). The mean and standard deviation (SD) for each metric were also 
calculated. Kruskal-Wallis tests were used to analyse the results. P values less than 0.05 were considered 
statistically significant. 
III. RESULTS 
The median MTV [IQR] of the reference GTVPET’s contoured using the 18F-FDG PET scans acquired after 1 
cycle of chemotherapy was 4.25 [2-7.16] mL; the median SUVmax [IQR] was 10.20 [5.23-12.59]. 
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A. Validation of ATLAASICT PET-AS method 
Figure 2 shows the mean DSC (+/- SD), Supplementary Data (B) shows the mean Sensitivity (+/- SD) and mean 
PPV (+/- SD) for all GTVPET-AS compared to the GTVPET delineated manually. The ATLAASORIG and ATLAASICT 
statistical models had a mean DSC [range] of 0.42 [0.00 – 0.80] and 0.72 [0.54 – 0.92], respectively. The mean 
Sensitivity [range] and PPV for ATLAASORIG was 0.59 [0.00 – 1.00] and 0.81 [0.00 – 1.00] respectively. Whereas, 
the mean Sensitivity [range] and PPV for ATLAASICT was 0.73 [0.37 – 1.00] and 0.80 [0.43 – 1.00]. A Kruskal-
Wallis test was used to compare all of the MTVs delineated by the GTVPET-AS and the GTVPET delineated and 
showed a significant difference (P = 0.0003) in the MTV between at least two of the delineation techniques. Table 
II shows the mean MTV, SUVmax, DSC, Sensitivity and PPV of the four best performing PET-AS methods, all 
with a mean DSC ≥ 0.6. A Kruskal-Wallis test compared the DSC, Sensitivity and PPV obtained for ATLAASICT, 
PT60, AT and WT. No significant difference was found between the DSC values (p = 0.07). A significant 
difference was found between the Sensitivity values (P = 0.02) and the PPV (p = 0.04) values. Further, SUVmax 
values obtained from the ATLAASICT, PT60, AT and WT volumes were compared using a Kruskal-Wallis test 
and no significant difference was found (p = 1). Figure 3 compares ATLAASICT derived contours with GTVPET 
volumes that were delineated manually. 
 
Fig 2: The DSC of GTVPET-AS contours compared to the GTVPET 
 
TABLE II 
THE MEAN MTV [RANGE] AND MEAN SUVMAX [RANGE] OF THE BEST FOUR PET-AS METHODS 
PET-AS Mean MTV [range] mL 
Mean SUVMAX 
[range] 
Mean DSC 
 (+/- STD) 
Mean Sensitivity 
(+/- STD) 
Mean PPV  
(+/- STD) 
ATLAASICT 6.01 [1.3 -24] 
10.19 [3.88 – 
25.00] 0.72 (+/- 0.10) 0.73 (+/- 0.19) 0.80 (+/- 0.19) 
PT60 8.66 [3.28 – 44.01] 
10.17 [3.18 – 
25.00] 0.61 (+/- 0.20) 0.81 (+/- 0.22) 0.64 (+/- 0.35) 
AT 3.85 [1.30 – 8.75] 
10.28 [4.12 – 
25.00] 0.63 (+/- 0.15) 0.61 (+/- 0.22) 0.79 (+/- 0.26) 
WT 7.20 [0.54 – 27.55] 
10.20 [3.39 – 
25.00] 0.60 (+/- 0.21) 0.75 (+/- 0.24) 0.60 (+/- 0.31) 
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Fig 3: ATLAASICT derived contours (Blue) and the GTVPET contours (Green) delineated jointly and by consensus 
in four of the FiGaRO patients. Good agreement is seen between the two contouring methods. However, slight 
variations exist. A) Patient 1, B) Patient 2, C) Patient 3, D) Patient 4
 
 
B. Comparison between GTVPET-AS and GTVPET 
Figure 4 shows the percentage increase in GTVPET-AS volume obtained from ATLAASICT, PT60, AT and WT 
PET-AS methods when compared to the GTVPET. In this study, the four best performing PET-AS methods 
delineated GTVPET-AS smaller than the GTVPET in 8 patients and larger in 6 patients. In 7 patients, there was a 
variation with some methods outlining a larger volume and some a smaller volume. Further, in patients 2,4,8, 10 
and 19, PT60 delineated larger GTVPET-AS volumes compared to the other PET-AS methods. A 651% and a 522% 
increase in patients 4 and 17 respectively. In these cases, the GTVPET MTV was less than or equal to 2 mL with a 
SUVmax of 4.73 and 5.23 respectively, suggesting GTVPET-AS delineation with PT60 is limited in MTV’s smaller 
than 2 mL. The two best performing methods (ATLAASICT and AT) agreed in the delineation of GTVPET-AS 
smaller or larger than the GTVPET in 19 patients. Current recommendations to reduce TVD variability are to 
standardise window width and levels for all patients [14,38]. In tumours with lower metabolic activity, 
standardised delineation parameters limit TVD due to reduced constrast compared to the background. ATLAASICT 
a) b) 
c) d) 
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and AT operate independently of window width and levels, therefore the agreement between the two methods to 
delineate smaller or larger volumes in 19 of the patients may highlight additional information in RT planning. 
 
Fig 4: The percentage increase in MTV delineated by PET-AS compared to the MTV of the GTVPET 
 
IV. DISCUSSION 
This study highlights challenges in TVD with 18F-FDG PET of the H&N, acquired after one cycle of ICT. We 
have shown that 1 cycle of ICT reduces the GTVPET volume and metabolic activity, making manual and automated 
delineation harder. In our study, GTVPET volumes defined using 42% SUVmax thresholding on diagnostic pre-
treatment and planning intra-treatment imaging resulted in mean volumes of 9.67 mL and 7.43 mL respectively. 
Ranging between 2.79 mL and 36.18 mL for diagnostic pre-treatment imaging and 3.81 mL and 15.11 mL for 
planning intra-treatment imaging. In IMRT planning, accurate TVD is critical as errors in delineation may increase 
geographical miss [18–20]. 18F-FDG PET discriminates biologically active tumour tissue with higher sensitivity 
and specificity compared to anatomical imaging and therefore, is increasingly being used for TVD [4–11]. 
However, manual TVD on PET/CT imaging in clinical practice is challenging [6,7] with relatively high levels of 
intra and inter-observer variability. 
 
Arens et al [38] in 2013 investigated the role of semi-automated PET-AS methods for TVD in sequential FLT 
PET/CT imaging in H&N carcinomas and their relationship with clinical outcome. Eighteen patients were treated 
with 3D-conformal RT and 28 patients were treated with IMRT. In total, 46 patients with a total of 48 GTVPET’s 
were treated with chemo-radiotherapy. FLT PET/CT imaging was acquired prior to treatment delivery (n = 46) 
and in the 2nd (n = 44) and 4th (n=28) weeks of treatment. In comparison, we analysed 18F-FDG PET imaging data 
acquired from 20 patients recruited to a prospective phase I feasibility study (FiGaRO), with PET/CT imaging 
acquired pre-ICT delivery and post one cycle of ICT. The GTVPET’s delineated by Arens et al were delineated by 
a singular trained radiation oncologist (clinical oncologist, UK), whereas in our study we reduced intra-observer 
variability with the use of a TVD protocol and joint delineation techniques. Arens et al also found that the 
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SUVPEAK derived on sequential FLT PET/CT scans significantly decreased during treatment, and the results 
presented in this study affirm their findings in 18F-FDG PET/CT imaging. Additionally, the GTVPET’s derived by 
PET-AS methods on the FLT based PET/CT imaging showed significant differences between the derived volumes 
(P < 0.05) and our study produced equivalent results. The FLAB method investigated in Arens et al [38] correlated 
with the manually derived GTVPET, whereas in our study the ATLAAS segmentation methodology was the best 
performing PET-AS method. A direct comparison of these two methods from the literature is impossible due to 
the different metrics used to assess the performance, the different scan acquisition parameters and the differing 
radiotracers. This highlights the requirement for a standardised evaluation dataset for assessing PET-AS method 
performance as highlighted by the AAPM Task Group No 211 [22] and by Berthon et al[39]. There have been 
several studies using deep learning to deal with PET or PET/CT segmentation, including the work from Czakon 
et al, that won the 2018 MICCAI PET segmentation challenge [40], based on a convolutional neural network. 
Work is in progress in our institution to implement similar technology in the ATLAAS segmentation workflow, 
 
In this study, we compared twenty-one manually delineated GTVPET’s with contours derived by PET-AS methods. 
Our results show that our machine-learned method, ATLAAS, has the potential to be trained and applied to a 
variety of imaging data whilst being the best performing PET-AS method. In previous work, ATLAAS has been 
described [31], trained upon and validated in diagnostic PET imaging [32]. However, this work demonstrates that 
new scans can be developed for which ATLAAS can be trained upon when the imaging characteristics of clinically 
obtained PET scans are significantly different from the default training dataset. Further to this, this work 
demonstrates that ATLAAS outperforms advanced PET-AS methods in low tumour to background ratio scenarios 
due to this additional training. Compared to non-machine learned PET-AS, ATLAAS had the highest DSC. 
Whilst, adaptive thresholding techniques were found to be more robust for accurate TVD compared to fixed 
thresholding techniques, the robustness of the machine-learned method ATLAAS was greater in comparison to 
all the other PET-AS methods included in this study, suggesting that it is an excellent candidate for ongoing 
multicentre studies using 18F-FDG PET for radiotherapy planning. 
 
Our results show that the performance of individual automated segmentation methodologies can be enhanced 
through the use of machine-learning techniques. Studies have shown how imaging parameters such as 
reconstruction settings [41] as well as tumour features impact TVD
 
[31,42–44]. The ATLAAS statistical model, 
however, was developed using tumour characteristics which have been demonstrated to be classifiers for accurate 
MTV delineation. These characteristics are MTV, NI and TBR [31,43,45]. Potentially, there are parameters which 
could impact the accuracy of the ATLAAS segmentation methodology, including morphological features [46] 
and the reconstruction modality. The results in this study, however, demonstrate that without the addition of the 
reconstruction modality as a classifier, and without the standardisation of the PET imaging, ATLAAS outperforms 
all of the included PET-AS methods. The standardisation of PET imaging acquisition and reconstruction is 
important for the accurate quantification of PET imaging in multicenter studies [47]. It has also been proposed 
that the use of consensus techniques, could improve the accuracy and the robustness of TVD [48] and we have 
shown that machine learning techniques can be used to select the most appropriate PET-AS method for a given 
FDG-PET image, without the requirement for multiple delineations of the GTVPET. 
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Our study also shows how ATLAAS is adaptable to differing situations and has been successfully trained on PET 
imaging data acquired after chemotherapy. This is a clear advantage of the ATLAAS machine learning-based 
approach compared to other PET-AS methods. Our study also supports published literature [22] in that no one 
single PET-AS method can be recommended for TVD after one cycle of ICT. However, machine learning based 
PET-AS methodologies are showing promise for the accurate TVD and based on our results, ATLAAS appears 
to be an excellent candidate for use in future trials. 
 
The results of this study are limited by a relatively small cohort (n = 20) of patients, although all recruited as 
part of the same clinical trial in OPSCC. Patients also underwent only one cycle of chemotherapy. Given the 
trial design, it was not possible to evaluate the accuracy and robustness of the PET-AS methods included in this 
study against the remaining biological tissue after multiple cycles of chemotherapy or after fractions of 
radiotherapy. However, this study demonstrates the feasibility of PET-AS TVD after one cycle of ICT. 
Therefore, ATLAAS could be useful as a basis for treatment adaptation (e.g. dose escalation) during 
chemotherapy. A further study to investigate the feasibility of PET-AS TVD in adaptive radiotherapy is 
planned. 
V. CONCLUSION 
The ATLAAS segmentation methodology provided a more robust approach to the delineation of the GTVPET 
after induction chemotherapy when compared to any of the individual PET-AS methods included in this study. 
ATLAAS is adaptable to differing situations and has been successfully trained on PET data acquired after 
chemotherapy and therefore could be useful as a basis for treatment adaptation (e.g. dose escalation) during 
chemotherapy. 
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